Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2020-12-31 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Sona Nanotech has received CE Mark approval for its rapid COVID-19 antigen test. It discusses regulatory approval, manufacturing plans, and forward-looking statements about sales and clinical trials. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about a regulatory milestone and product commercialization, not a financial report or filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial filing. It is also not a report publication announcement or certification. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and corporate news that does not fit other specific categories.
2020-12-31 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is a Form 45-106F1 Report of Exempt Distribution, which is a regulatory filing used in Canada to report distributions of securities under exemptions from prospectus requirements. It includes detailed information about the issuer, distribution dates, types of securities distributed, purchaser information, jurisdictions, exemptions relied upon, and compensation related to the distribution. This form is a regulatory compliance document rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management analysis but is a formal regulatory disclosure. Therefore, it fits best under the category of Regulatory Filings (RNS).
2020-12-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109FV2) signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2020. It explicitly states it is a certification of interim filings for a venture issuer and does not contain the actual financial data or detailed financial statements. The document is primarily an officer certification letter, not the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR). The document length is short (3045 characters), consistent with a certification letter rather than a full report.
2020-12-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Sona Nanotech Inc. commenting on unusual market activity in its shares. It includes disclaimers about forward-looking statements and regulatory approvals but does not contain any financial statements, detailed financial results, or regulatory filings. It is a market activity commentary and not a financial report, earnings release, or regulatory filing. The document is relatively short (5166 characters) and serves as a public announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-10 English
News release - English.pdf
Regulatory Filings
2020-12-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private placement financing by Sona Nanotech Inc., detailing the terms of the financing, use of proceeds, and appointment of an EU agent for CE Mark application. It focuses on fundraising activities and regulatory compliance steps related to product certification. There are no financial statements, quarterly or annual results, or detailed management discussion of financial performance. The document is not a report but an announcement of financing and regulatory steps. Therefore, it fits best under Capital/Financing Update (CAP). The document length (7770 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2020-12-03 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.